Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.

Autor: Tannir, Nizar M., Cohen, Lorenzo, Wang, Xuemei, Thall, Peter, Mathew, Paul F., Jonasch, Eric, Siefker-Radtke, Arlene, Pagliaro, Lance C., Ng, Chaan S., Logothetis, Christopher
Zdroj: Cancer (0008543X); Nov2006, Vol. 107 Issue 9, p2254-2261, 8p
Databáze: Complementary Index
Externí odkaz: